Bio Green Med Solution (BGMS) Income from Continuing Operations (2010 - 2026)
Bio Green Med Solution (BGMS) posted quarterly Income from Continuing Operations of 197000.0 for Q1 2026, up 95.32% year-over-year from 100862.08 in Q1 2025, and down 4040.0% quarter-over-quarter from 5000.0 in Q4 2025.
Analysis
Bio Green Med Solution (BGMS) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Bio Green Med Solution (BGMS) has reported Income from Continuing Operations for 17 consecutive years, with 197000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 95.32% year-over-year to 197000.0; the TTM figure through Mar 2026 stood at 2498000.0 (down 291.71% YoY), while the FY2025 annual figure was 2382000.0, down 192.94% from the prior year.
- Income from Continuing Operations fell to 197000.0 in Q1 2026 per BGMS's latest filing, from 5000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 15285000.0 in Q4 2022 and bottomed at 6032000.0 in Q3 2023.
- Historically, Income from Continuing Operations has averaged 1434352.94 across 5 years, with a median of 3257000.0 in 2024.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations surged 1414.87% — and 2023, when it plunged 129.21%.
- Bio Green Med Solution's Income from Continuing Operations stood at 15285000.0 in 2022, then slumped by 129.21% to 4465000.0 in 2023, then soared by 340.16% to 10723000.0 in 2024, then plunged by 99.95% to 5000.0 in 2025, then slumped by 4040.0% to 197000.0 in 2026.
- Business Quant data shows BGMS's Income from Continuing Operations at 197000.0 in Q1 2026, 5000.0 in Q4 2025, and 988000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn | 600.00 Mn |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Bio Green Med Solution | 5.21 Mn | 1.42 Mn | 79,000.00 | -405,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -405,000.00 |
| Mar 31, 2026 | -197,000.00 |
| Dec 31, 2025 | 5,000.00 |
| Sep 30, 2025 | -988,000.00 |
| Jun 30, 2025 | -1.25 Mn |
| Mar 31, 2025 | -4.21 Mn |
| Dec 31, 2024 | -1.34 Mn |
| Sep 30, 2024 | -1.96 Mn |
| Jun 30, 2024 | -3.26 Mn |
| Mar 31, 2024 | -2.95 Mn |
| Dec 31, 2023 | -2.90 Mn |
| Sep 30, 2023 | -6.03 Mn |
| Jun 30, 2023 | -5.45 Mn |
| Mar 31, 2023 | -5.80 Mn |
| Dec 31, 2022 | -6.69 Mn |
| Sep 30, 2022 | -5.10 Mn |
| Jun 30, 2022 | -4.58 Mn |
| Mar 31, 2022 | -4.11 Mn |
| Dec 31, 2021 | 9.18 Mn |
| Sep 30, 2021 | -6.63 Mn |